GE HealthCare Technologies Inc. (NASDAQ:GEHC) Announces Quarterly Dividend of $0.03

GE HealthCare Technologies Inc. (NASDAQ:GEHC) declared a quarterly dividend on Wednesday, September 18th, Zacks reports. Investors of record on Friday, October 18th will be given a dividend of 0.03 per share on Friday, November 15th. This represents a $0.12 annualized dividend and a yield of 0.13%. The ex-dividend date is Friday, October 18th.

GE HealthCare Technologies has a dividend payout ratio of 2.5% indicating that its dividend is sufficiently covered by earnings. Research analysts expect GE HealthCare Technologies to earn $4.72 per share next year, which means the company should continue to be able to cover its $0.12 annual dividend with an expected future payout ratio of 2.5%.

GE HealthCare Technologies Trading Up 2.4 %

Shares of GEHC opened at $90.62 on Friday. The firm has a market cap of $41.36 billion, a P/E ratio of 26.50, a price-to-earnings-growth ratio of 3.26 and a beta of 1.17. GE HealthCare Technologies has a fifty-two week low of $62.35 and a fifty-two week high of $94.50. The company has a debt-to-equity ratio of 1.05, a quick ratio of 0.82 and a current ratio of 1.06. The business has a 50-day moving average of $83.64 and a 200 day moving average of $83.31.

GE HealthCare Technologies (NASDAQ:GEHC) last released its quarterly earnings data on Wednesday, July 31st. The company reported $1.00 earnings per share for the quarter, beating analysts’ consensus estimates of $0.98 by $0.02. The business had revenue of $4.84 billion during the quarter, compared to analyst estimates of $4.88 billion. GE HealthCare Technologies had a net margin of 8.10% and a return on equity of 25.26%. GE HealthCare Technologies’s revenue was up .5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.92 EPS. As a group, research analysts forecast that GE HealthCare Technologies will post 4.26 EPS for the current year.

Insider Buying and Selling at GE HealthCare Technologies

In related news, CEO Thomas J. Westrick sold 2,750 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $80.78, for a total transaction of $222,145.00. Following the sale, the chief executive officer now directly owns 17,509 shares of the company’s stock, valued at approximately $1,414,377.02. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.27% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

GEHC has been the subject of a number of analyst reports. JPMorgan Chase & Co. started coverage on shares of GE HealthCare Technologies in a research report on Monday, September 9th. They issued a “neutral” rating and a $90.00 price objective for the company. Stifel Nicolaus started coverage on shares of GE HealthCare Technologies in a research note on Tuesday, August 6th. They set a “buy” rating and a $100.00 price objective for the company. The Goldman Sachs Group began coverage on GE HealthCare Technologies in a research report on Thursday, May 30th. They set a “neutral” rating and a $87.00 price objective on the stock. Redburn Atlantic upgraded GE HealthCare Technologies to a “strong-buy” rating in a report on Thursday, August 1st. Finally, BTIG Research upgraded GE HealthCare Technologies from a “neutral” rating to a “buy” rating and set a $100.00 price objective for the company in a report on Wednesday. Six investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $95.00.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.